Brief: Onxeo: Final Results Of DRIIV Phase 1 Dose-Escalation Study Of Asidna

Valerio Therapeutics SA

27/08/2020 17:11

Aug 27 (Reuters) - Onxeo SA  C4X.PA :
    * PUBLICATION OF FINAL RESULTS OF DRIIV PHASE 1DOSE-ESCALATION STUDY OF ASIDNA™ IN ADVANCED
SOLID
TUMORSIN BRITISH JOURNAL OF CANCER
    * ACTIVE DOSE OF 600 MG WAS DETERMINED TO BE OPTIMAL DOSE FOR USE IN COMBINATION
    * DOSE IS CURRENTLY BEING USED IN EVALUATION OF ASIDNA™ IN COMBINATION WITH CHEMOTHERAPIES
(DRIIV-1B STUDY) AND A PARP INHIBITOR (REVOCAN STUDY)

Source text: https://bit.ly/32yASqe
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))